Skip to main content
The Patent Truth About Health, Innovation and Access
Heer Pardesi, who is 42 years old, holds her antiretroviral drugs for HIV. (Jonas Gratzer/LightRocket via Getty Images)

The Patent Truth About Health, Innovation and Access

Carol Adelman

View PDF

This report reviews and analyzes the following premises of the U.N.‘s High Level Panel on Access to Medicines, which are:

  1. Millions of poor people in low- and middle-income countries have been denied access to antiretroviral drugs and other medicines;
  2. Patents are the main cause of higher costs of medicines for poor people in low- and middle-income countries;
  3. The intellectual property system, including patents and voluntary licenses, limits research and disadvantages local producers in low- and middle- income countries.

These basic assumptions, drawing from the earlier Global Commission on HIV and the Law and the new High Level Panel on Access to Medicines, however, are not supported by global health research.

View PDF

Related Articles

2021 Annual Report

Hudson Institute

2021 began with most of the United States still shuttered by the COVID-19 pandemic— and ended with most of the world on edge due to the massing of Rus...

Continue Reading

Big Tech's Sticky Fingers Are Still at Work in Washington

Adam Mossoff

Big Tech is strongly criticized in Congress these days, but it still has sway in Washington when it lobbies Congress to weaken the U.S. patent system....

Continue Reading

Protecting Our Nation's Back Doors: Improving Patent Policy for National Security

Kristen Osenga

In 2020, US officials announced that Huawei Technologies had the ability to secretly access mobile phone networks through “back doors” originally ...

Continue Reading